Pinnacle Bancorp Inc. Sells 1,166 Shares of CVS Health Corporation (NYSE:CVS)

Pinnacle Bancorp Inc. lessened its stake in CVS Health Corporation (NYSE:CVS) by 60.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 766 shares of the pharmacy operator’s stock after selling 1,166 shares during the period. Pinnacle Bancorp Inc.’s holdings in CVS Health were worth $52,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of CVS. Whitebox Advisors LLC bought a new position in shares of CVS Health in the fourth quarter worth approximately $249,000. Fairfax Financial Holdings Ltd. Can purchased a new stake in CVS Health during the 4th quarter valued at $121,742,000. Lazard Asset Management LLC grew its holdings in CVS Health by 7.3% in the 4th quarter. Lazard Asset Management LLC now owns 4,290,953 shares of the pharmacy operator’s stock worth $192,617,000 after acquiring an additional 293,406 shares during the last quarter. Seizert Capital Partners LLC increased its position in shares of CVS Health by 22.8% in the fourth quarter. Seizert Capital Partners LLC now owns 569,527 shares of the pharmacy operator’s stock valued at $25,566,000 after acquiring an additional 105,708 shares during the period. Finally, Capital World Investors raised its stake in shares of CVS Health by 26.6% during the fourth quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator’s stock valued at $2,739,927,000 after acquiring an additional 12,819,148 shares during the last quarter. 80.66% of the stock is currently owned by hedge funds and other institutional investors.

CVS Health Price Performance

CVS stock opened at $66.44 on Thursday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.63 and a current ratio of 0.82. The firm has a market capitalization of $84.05 billion, a price-to-earnings ratio of 15.86, a PEG ratio of 0.97 and a beta of 0.56. The firm has a 50 day moving average price of $64.81 and a 200-day moving average price of $60.62. CVS Health Corporation has a 52-week low of $43.56 and a 52-week high of $72.51.

CVS Health (NYSE:CVS) last released its earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 EPS for the quarter, topping the consensus estimate of $1.62 by $0.63. CVS Health had a return on equity of 10.59% and a net margin of 1.39%. The business had revenue of $94.59 billion for the quarter, compared to the consensus estimate of $93.07 billion. During the same period in the previous year, the company posted $1.31 earnings per share. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. Equities research analysts forecast that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

Insider Buying and Selling at CVS Health

In other CVS Health news, Director Guy P. Sansone bought 1,570 shares of CVS Health stock in a transaction on Thursday, June 5th. The stock was acquired at an average price of $63.70 per share, with a total value of $100,009.00. Following the acquisition, the director now owns 12,007 shares in the company, valued at approximately $764,845.90. This trade represents a 15.04% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.22% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

CVS has been the topic of a number of research analyst reports. Piper Sandler boosted their price target on CVS Health from $72.00 to $74.00 and gave the company an “overweight” rating in a report on Friday, March 21st. Morgan Stanley reissued an “overweight” rating on shares of CVS Health in a research note on Tuesday, April 15th. Cowen reaffirmed a “buy” rating on shares of CVS Health in a research note on Monday, May 5th. Royal Bank Of Canada boosted their price objective on shares of CVS Health from $74.00 to $81.00 and gave the company an “outperform” rating in a research report on Monday, May 5th. Finally, UBS Group raised their target price on shares of CVS Health from $67.00 to $71.00 and gave the stock a “neutral” rating in a research report on Friday, May 2nd. Two research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, CVS Health currently has a consensus rating of “Moderate Buy” and an average target price of $74.75.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.